Levetiracetam Teva

Levetiracetam, the active ingredient in Levetiracetam Teva, is an anticonvulsant presented as an injectable solution for intravenous use. It is employed as adjunctive therapy for partial‑onset seizures and generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products for the global market. The company follows EU GMP standards and offers reliable cold‑chain logistics for injectable medicines, supporting timely delivery to healthcare providers.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: reduces seizure frequency as an adjunct to existing antiepileptic therapy. - Generalized tonic‑clonic seizures: provides additional seizure control when combined with other agents. - Refractory epilepsy: offers an alternative option for patients whose seizures are not adequately controlled by other medications.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Irritability

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior

When using Levetiracetam injectable solution, several precautions should be observed to ensure patient safety.

- Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests and consider dose modification. - Concomitant CNS depressants: increased risk of sedation and respiratory depression. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Behavioral changes: monitor for aggression, mood swings, or suicidal ideation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam plasma levels. - Phenobarbital: reduces levetiracetam concentrations, potentially decreasing effectiveness. - Phenytoin: may decrease levetiracetam exposure, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase risk of central nervous system side effects. - Alcohol or other CNS depressants: enhanced sedation and respiratory depression.